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Antibioticcterial resistance to conventional antibiotic compounds and the need for new
antibiotics have stimulated interest in the development of antimicrobial peptides (AMPs) as human
therapeutics. Development of topically applied agents, such as pexiganan (also known as MSI-78, an analog
of the naturally occurring magainin2, extracted from the skin of the African frog Xenopus laevis) has been the
focus of pharmaceutical development largely because of the relative safety of topical therapy and the
uncertainty surrounding the long-term toxicology of any new class of drug administered systemically. The
main hurdle that has hindered the development of antimicrobial peptides is that many of the naturally
occurring peptides (such as magainin), although active in vitro, are effective in animal models of infection
only at very high doses, often close to the toxic doses of the peptide, reﬂecting an unacceptable margin of
safety. Though MSI-78 did not pass the FDA approval, it is still the best-studied AMP to date for therapeutic
purposes. Biophysical studies have shown that this peptide is unstructured in solution, forms an antiparallel
dimer of amphipathic helices upon binding to the membrane, and disrupts membrane via toroidal-type pore
formation. This article covers functional, biophysical, biochemical and structural studies on pexiganan.
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There is a pressing need for the development of novel antimicro-
bial therapies due to the emergence of antibiotic resistant bacterial
strains. In the United States, the Center for Disease Control (CDC) has
reported that approximately 1.7 million cases of healthcare-associate
infection resulting in 99,000 deaths are occurring annually [1]. Among
these the major sites of infection are urinary tract, surgical site, lung
and blood stream [1]. The long standing and continuing problemorthy).
ll rights reserved.posed by antimicrobial resistant bacterial strains is exempliﬁed by
Staphylococcus aureus and Streptococcus pneumoniae.
Methicillin resistant S. aureus (MRSA) was reported as early as
1961 with wide spread occurrences by 1991 [2,3]. Later, reports of
reduced susceptibility to vancomycin were made in 1997 [4] followed
by isolation of vancomycin resistant S. aureus in 2003 [5]. S.
pneumoniae serotype 19A was reported in 2007 which is resistant to
all US Food and Drug Agency approved antimicrobial agents [6].
The emergence of bacterial strains resistant to most or all of the
clinically useful antibiotics has provided the impetus to develop new
classes of antibiotics that may combat bacterial resistance more
effectively. Antimicrobial peptides (AMPs) show promise as thera-
peutic agents against a broad spectrum ofmicrobes including bacteria,
Table 1
Minimum inhibitory concentrations for aerobic and anaerobic bacterial strains and
percentage of strains susceptible to inhibition by Pexiganan or oﬂoxacin from literature
values.
Bacteria strain MIC Pexiganan
(μg/mL)
% Strains
susceptible at
≤64 μg/mL
% Strains
susceptible
to oﬂoxacin
at ≤2 μg/mL
Ref. [53] Ref. [54] Ref. [53] Ref. [54] Ref. [53]
Aerobic bacteria
Acinetobacter sp. 8 8 100 100 100
Alcaligenes faecalis N/A 256 100 71 80
Citrobacter diversus 16 8 100 99 100
Citrobacter freudii 16 8 96 100 92
Corynebacterium
jeikeium
4 8 100 100 100
Enterobacter
aerogenes
16 32 100 100 100
Enterobacter cloacae 32 64 96 92 100
Escherichia coli 16 32 100 100 83
Klebsiella oxytoca 16 16 100 99 100
Klebsiella pneumoniae 16 16 100 100 100
Psuedomonas
aeruginosa
16 16 100 99 100
Staphylococcus aureus
(MRSA)
64 100 20
Staphylococcus aureus
(MSSA)
16 16 100 100 93
Staphylococcus
epidermidis
8 8 100 100 100
Staphylococcus
haemolyticus
8 8 100 100 100
Streptococcus
agalactiae
32 16 100 100 92
Streptococcus
pyogenes
32 8 97 99 96
Anaerobic bacteria
Bacteroides fragilis 6 4 100 100 67
Bacteroides ovatus 6 8 100 100 0
Clostridium
perfringens
18 64 100 90 100
Clostridium ramosum 16 16 100 100 0
Clostridium
sporogenes
6 16 100 100 100
Peptostretococcus
anaerobius
45 32 100 91 100
Peptostreptococcus
magnus
1 8 100 97 0
Prevotella bivia 69 32 78 94 100
Prevotella
melaninogenica
51 64 100 91 33
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they form part of the initial line of defense in the innate immune
system and are also implicated in the activation of the adaptive
immune response against microbes [10]. The innate and adaptive
immune effects of mammalian AMPs, such as defensins and cathe-
licidin-derived peptides, include antimicrobial activity [8,11–13],
antiviral activity [14], degranulation of mast cells [15,16], promotion
or enhancement of antigen, cytokine and chemokine response [17,18].
Anticancer activities of AMPs have also been reported [19–21].
Although highly diverse in sequence and structure, almost all AMPs
share the property of being highly amphipathic, with one face of the
peptide being hydrophobic and the other face presenting a cluster of
positively charged residues [22,23]. AMPs are often classiﬁed based on
the structural characteristics of the peptides. These classiﬁcations
includeα-helical, linear, or disulﬁde bonded [8]. Thenumberof disulﬁde
bonds ranges from 1 to 4 and results in β-hairpin-like structures [13].
Naturally occurring AMPs with α-helical structures include
cecropins from insects and mammals [24], magainins from frogs
[25,26], and cathelicidins frommammals [11,27]. Linear AMPs include
indolicidin, a tryptophan rich peptide from cows and PR-39, a proline/
arginine rich peptide from pigs [28,29]. The disulﬁde bond containing
AMPs includes polyphemusin [30,31] and tachyplesin [32,33] from
horseshoe crab, protegrin-1 from pig [34,35], human-β-defensin-3
[13], and α-defensin (HNP3) from humans [36].
The length of AMPs ranges from ∼12 to 50 amino acids making
them reasonably easy to synthesize. This has led to a vast number of
studies that systematically investigate the importance of amino acid
composition, peptide length, net charge, and hydrophobicity on the
antibacterial activity of AMPs [37,38]. These investigations and
mechanistic studies on gene-encoded AMPs have provided much
insight into the mechanisms of AMPs.
Whereas some AMPs have been determined to act intracellularly
[39], most appear to function primarily by disrupting bacterial cell
membranes [40,41]. Bacterial cell membranes contain predominantly
negatively charged phospholipids that give rise to an electrostatic
attraction to the highly cationic AMPs. On the other hand, eukaryotic
membranes, which contain predominantly neutral phospholipids, are
usually less susceptible to disruption by AMPs. In addition the
presence of cholesterol in eukaryotic membranes increases the
resistance against membrane disruption by AMPs. Upon association
with the membrane, unstructured peptides become structured and
begin thinning the bacterial membrane and proceed to disrupt the
membrane through one of three broadly deﬁned methods. The barrel
stavemethod involves peptide insertion into themembrane parallel to
the lipid bilayer normal, the toroidal pore method induces bending of
the lipid bilayer resulting in pores in themembranewhere lipids tilt in
such a way that the lipid head groups deﬁne the surface of the pore,
and the micellization model results in the degradation of membranes
through the formation of lipid encompassed peptides [11,42,43]. There
are other mechanisms, generally categorized as carpet mechanism,
that destabilize the membrane structure to cause cell death.
There is extensive literature and general reviews on AMPs and
their mechanisms. In this article, we have speciﬁcally focus on
Pexiganan or MSI-78 and its very promising attributes. Within this
review we describe the process by which the AMP Pexiganan was
developed, the antimicrobial activity of the peptide and the high-
resolution biophysical characterization of the structure and mechan-
ism of Pexiganan. The potential therapeutic applications of Pexiganan
and further developments of Pexiganan analogs are also discussed.
2. Pexiganan or MSI-78
Among the hundreds of gene-encoded and designed AMPs,
magainin-2 and its analogs have been very well studied; amino acid
sequences are given in Fig. 1. Magainin-2 was co-discovered in 1987
after scientists found that Xenopus laevis were able to remaininfection-free upon making incisions in the frogs' skin and placing
the frog in water containing high levels of microbes [43,44]. Two
peptides were isolated from X. laevis, magainin-1 and 2. The 23 amino
acid magainin-2 was soon found to have broad-spectrum antibacterial
and antifungal activity [45,46]. Many synthetic analogs of magainin-2
have been developed to maximize the broad spectrum activity of the
peptide in hopes of developing a clinically useful antimicrobial
therapeutic agent.
Zasloff et al. discovered that removal of amino acid residues from
the N-terminus of magainin-2 resulted in a loss of activity [45].
Omission of residues past Lys4 was particularly detrimental to the
activity of the peptide lower the MIC at least 30× for E. coli in
comparison to magainin-2 [45]. Removal of amino acid residues from
the C-terminus of the peptide also negatively affected the activity of
the peptide signiﬁcantly [45]. These results suggested that the
minimal peptide length was important potentially due to the
mechanism of the peptide.
The helical content of the peptide was explored as a potential
target for improving the activity of magainin by Chen et al. [46]. Gly to
Ala substitution, which were made to increase the stability of the α-
helical structure, resulted in improved activity and attempts to disrupt
Fig. 1. Amino acid sequences of naturally-occurring magainins (magainin-1 and 2) and
MSI-78 or pexiganan, designed based on magainin 2. Helical wheel diagrams of
magainin 2 and MSI-78 illustrate the amphipathicity of the peptide in helical form.
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decrease the activity of the peptide [46]. These studies established the
importance of the secondary structure of the peptide upon association
with the cell membrane [46,47].
Systematic single amino acid mutations to the peptide were
performed by Cuervo et al. C-terminal amidation was found to
increase peptide activity as well as removal of Glu19 [48]. Poly-lysine
and poly-arginine sequences appended to the termini of magainin-2
were also developed with the intent of improving the electrostatic
attraction of AMP for anionic bacterial membranes [49]. The resulting
peptides did not show increased activity.
With the information available from previous research Zasloff and
coworkers of Magainin Pharmaceuticals did an extensive SAR study
that resulted in the development of MSI-78 or Pexiganan which
entered clinical trials for topical treatment of diabetic foot ulcers [50].
In 1999 the FDA denied approval of pexiganan after completion of two
phase III clinical trials that revealed pexiganan was no more effective
than already approved treatments for diabetic foot ulcers and required
addition clinical trials for consideration [51]. Magainin Pharmaceu-
ticals became Genaera Corporation followed by the recent acquisition
of worldwide rights to pexiganan by MacroChem. Improvements in
clinical trial design, greater understanding of diabetic foot ulcers and
topical anti-infective treatments, and advances in peptide manufac-
turing keep hopes alive regarding the potential FDA approval of
pexiganan [52].
3. Activities of Pexiganan
Extensive in vitro studies have been conducted to determine the
minimum inhibitory concentration of pexiganan for a diverse array ofFig. 2. Monomeric (a) and antiparallel dimeric (b) helical structures of MSI-78 determined
showing the hydrophobic interface (green) and hydrophilic exterior (blue) of the dimeric he
more hydrophilic surface exposed for the membrane interaction and hydrophobic residues a
Gram positive and Gram negative) bacterial membranes is increased. Therefore, the toxicitymicrobes. The major categories of microbes that are of interest as
potential targets for Pexiganan have included both aerobic and
anaerobic, as well as Gram positive and Gram negative bacteria.
Table 1 summarizes the MIC values obtained for Pexiganan from two
sources with comparative ﬁgures for oﬂoxacin, the FDA approved drug
used as a comparative treatment in the phase III clinical trials of
Pexiganan [53,54]. The results clearly show the effectiveness and
broad spectrum activity of Pexiganan in vitro. In addition, attempts to
generate resistance in bacteria by repeated treatment at subinhibitory
concentration of the peptidewere unsuccessful. Importantly, S. aureus,
a bacteria that has quickly developed multiple resistance to current
antimicrobial compounds including methicillin and vencomycin [2–5]
was included in these attempts and showed no resistance to
Pexiganan [54].
Kinetcis of Pexiganan cytotoxicity were studied for E. coli and S.
aureus at 50 μg/mL. Colony forming units were reduced to zero by
30 min for E. coli and 60 min for S. aureus [55]. These results show the
rapid onset of activity displayed by Pexiganan in vitro. The broad-
spectrum activity, low propensity for generating resistance and quick
onset of activity are ideal characteristics for potential therapeutics.
The potential toxicity of Pexiganan has been established by measuring
the hemolytic activity of the peptide against human red blood cells.
Reported numbers suggest that a concentration of at least 250 μg/mL
are necessary to induce 100% hemolysis [55–57], much below the MIC
for many of the bacterial strains listed in Table 1. This exempliﬁes the
high selectivity against erythrocytes and, in turn, low likelihood of
toxicity. In addition, no adverse side effects were reported during the 2
phase III clinical trials described in detail in Ref. [58]. The promising
attributes of Pexiganan have led to detailed studies regarding the
structure and mechanism of the peptide.
4. Structural studies
Solving the secondary structure of an AMP has been considered to
be an important step in understanding its function and will be useful
in developing potent peptides for pharmaceutical applications. While
global structure analysis of AMPs using low-resolution techniques like
CD and FTIR usually provides a quick information on the experimental
conditions under which a conformational change occur, atomistic-
level resolution three-dimensional structures can provide high-
resolution information on peptide–peptide and peptide–membrane
interactions. Such high-resolution structural information are powerful
in understanding the role of individual amino acids in the formation of
oligomers in solution or in a membrane environment and in providing
insights into themechanism of cell lysis. Belowwe cover the structural
studies on pexiganan in solution and in model membranes.
Circular dichroism studies have shown that MSI-78 is unstructured
in solution and forms anα-helix in the presence of lipids or detergents
[59]; a number of biophysical studies reported similar behavior for
magainin-2 and its membrane interaction is also well establishedby NMR experiments in a membrane environment [67]. (c) A surface representation
lical structure. The formation of a dimer is a key step in its activity. Since the dimer has
re not exposed outside, the selectivity of the peptide towards negatively charged (both
of the peptide is further reduced.
Fig. 3.Mechanism of membrane disruption by MSI-78. (a) NMR studies have shown that MSI-78 is unstructured in solution and forms a helix in a membrane environment [59,67].
The amphipathic peptide is aligned near the surface of the membrane [59]. (b) Positive curvature strain induced by the peptide is determined from 31P solid-state NMR on POPE
bilayers and differential scanning calorimetry experiments on DiPoPE bilayers [81]. (c) Formation of toroidal pores was determined from solid-state NMR studies [81]. (d) Solid-state
NMR studies revealed the formation of normal hexagonal phase structure of lipids at higher concentrations (N10 mol%) of MSI-78 [59,81]. (e) Solid-state NMR experiments revealed
that a couple of weeks old samples exhibited the formation of bicelles and then micellization due to the detergent-like behavior of the peptide [results unpublished].
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a β-turn structure when in methanol or dimethylsulfoxide [63]. The
highly cationic nature of the peptide results in a random coil structure
in aqueous solution due to electrostatic repulsion between lysine side
chains. While this property is similar to most linear AMPs that are not
structured in water or ionic solutions, the only human member of the
cathelicidin-derived peptides, LL-37, forms a helical structure either in
the presence ions or at high peptide concentration as it forms helical
oligomers [64–66]. Upon association with the membrane surface,
particularly anionic lipid head groups, a charge balance is achieved and
Pexiganan assumes an α-helical structure [59].
The high-resolution structure, oligomerization state, and orienta-
tion of membrane associated Pexiganan has been studied by NMR
spectroscopy [59,67]. A dimeric antiparallel α-helical coiled-coil
structure is formed on association with dodecylphosphocholine
micelles and bilayers [67]. The interface of the dimer is a ‘phenyla-
lanine zipper’ composed of three phenylalanine side chains per helix
(Fig. 2). The leucine and isoleucine residues near the termini of the
helices also pack together at the dimer interface. The importance of
the three phenylalanine residues in the self-association of Pexiganan
is conﬁrmed by the fact that MSI-594, which lacks 2 of the 3
phenylalanine residues, does not oligomerize in a membrane
environment [67]. Solid-state NMR studies on mechanically aligned
model membranes and multilamellar vesicles of phospholipids [68],
and chemical crosslinking with glutaraldehyde [69], also suggest that
Pexiganan self-associates to form dimers in the presence of lipid
vesicles. Interestingly, magainin-2 is also a random coil in solution and
forms a dimeric antiparallel helical structure in dilauroylphosphati-
dylcholine vesicles at a higher concentration than that of MSI-78
(Fig. 2) [70]. A recent solid-state NMR study utilized REDOR (rotational
echo double resonance) [71]MAS (magic angle spinning) experiments
on selectively labeled peptides to determine the backbone conforma-
tion of pexiganan in phospholipids bilayers [67]. Structural analysis
revealed that the structure of pexiganan is the same in detergent
micelles and in lipid bilayers.
5. Topology of pexiganan in membranes
In addition to the high-resolution structure, folding and topology
(or membrane orientation) of an AMP is essential to fully understand
the functional properties of an AMP. For example, the exact membraneorientation of an AMP can provide insights into the mechanism by
which an AMP lyse bacterial cells. Solid-state NMR experiments on
aligned samples have been used to obtain this information on several
AMPs. Difﬁculties related to the preparation of fully-hydrated and
stable bilayers for this purpose have been overcome by a newly
developed naphthalene procedure [72]. This successful preparation of
mechanically aligned glass-plate bilayer samples has been vital in the
investigation of a number of AMPs [59,64,72,73]. 2D PISEMA
(polarization inversion spin exchange at the magic angle) [74] solid-
state NMR experiments on mechanically aligned bilayers containing
15N-labeled pexiganan peptides were used to measure 15N chemical
shifts and 1H–15N dipolar couplings associated with amide sites of the
peptide. These NMR parameters revealed that the helical pexiganan is
oriented near the surface of the membrane [59]. These results ruled
out the barrel-stave type mechanism of membrane disruption (or
channel formation) by pexiganan. Similar observations have also
reported for magainin-2 peptide [75,76]. On the other hand, based on
19F [77] and 2H [78] solid-state NMR experiments on PGLa embedded
in lipid bilayers the authors have suggested that the helical peptide
initially binds to the membrane surface and then forms dimers that
are tiled by inserting into the hydrophobic region of the membrane.
These studies have shown that solid-state NMR experiments on ﬂuid
and physiologically-relevant lipid bilayers provide insights into the
function of antimicrobial peptides that are difﬁcult to obtain by other
means. It should also be mentioned here that care must be taken in
interpreting solid-state NMR data obtained from samples that are not
physiologically relevant.
6. Mechanistic studies
The mechanism of membrane interaction and disruption has been
established via ﬂuorescence assays, calorimetric techniques, micro-
scopy, solid-state NMR spectroscopy and neutron diffraction. The
consensus is that Pexiganan exerts its antibacterial effect by forming
toroidal pores in the bacterial membrane (Fig. 3).
Cell membrane disruption by Pexiganan was conﬁrmed by
monitoring the uptake or leakage of ﬂuorescent molecules from
either E. coli or lipid vesicles, respectively [59]. Pexiganan effectively
induced the uptake of ANS into E. coli cell membranes as well as
inducing the leakage of carboxyﬂuorescence from POPC/POPG (3:1)
vesicles, a model system for bacterial cell membranes. In both studies,
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Pexiganan, indicating the rapid onset of membrane disruption by the
peptide [59].
Isothermal titration calorimetry reveals that the association of
Pexiganan to lipid vesicles is exothermic with a binding enthalpy of
−14.4 kcal/mol [79] and is in agreement with measurements on
magainin-2 which has a ΔH=−17.0 kcal/mol [80]. The binding
enthalpies of cationic peptides have been attributed primarily to the
electrostatic interactions between the peptide and the lipid head
groups.
The effect of the peptide on lipid bilayers has been very
informative of the mechanistic route of Pexiganan [81]. Differential
scanning calorimetry (DSC) and NMR spectroscopic studies have
pinpointed the formation of toroidal pore formation by Pexiganan in
lipid bilayers [81]. DSC experiments in DiPoPE show a concentration
dependant increase in the ﬂuid lamellar to inverted hexagonal phase
transition of the bilayer which supports the induction of positive
curvature strain on the lipid bilayer upon incorporation of Pexiganan
[81]. 31P NMR also showed that Pexiganan inhibited the ﬂuid lamellar
to inverted hexagonal phase transition and 15N NMR supporting the
formation of toroidal pores in the lipid bilayer due to the orientation of
the peptide perpendicular to the bilayer normal [59,81]. Solid-state
NMR results from mechanically aligned bilayers were used to
determine the toroidal pore geometry in the presence of pexiganan.
Solid-state NMR studies on bicelles containing MSI-78 showed the
peptide-induced disorders in the hydrophobic region of the lipid
bilayer and also the detergent behavior of the peptide [82]. The
signiﬁcant reduction in the 14N quadrupole coupling observed from
the choline head group of the lipid in bilayers containing pexiganan
[66] and molecular dynamic simulations [83] revealed the electro-
static interactions between the positively charged residues of the
peptide and the phosphate O− atom of the lipid head group.
Membrane thinning effects of Pexiganan have been visually
observed using atomic force microscopy (AFM). Mecke et al. present
images of supported lipid bilayers composed of DMPC in the presence
and absence of Pexiganan [84]. There is an obvious thinning of the
bilayer as a function of time in the presence of the peptide.
7. Can Pexiganan be made more potent?
Although promising as broad-spectrum antibiotics, MSI-78 and
other AMPs are susceptible to proteolysis in vivo by endogenous or
bacterial proteases, which may considerably diminish their effective-
ness for intravenous applications. Studies on Leishmania pinpoint
leishmanolysin as the preventative factor in AMP induced apoptosis of
the bacteria [85]. Attempts to overcome this problem by increasing
the dose of the AMP often lead to toxic side effects, most notably lysis
of red blood cells, which has been attributed to non-speciﬁc
hydrophobic interactions between the peptide and the eukaryotic
cell membrane [86]. Improvements to the stability and/or activity of
Pexiganan would be signiﬁcant for the potential application of
Pexiganan, or derivatives thereof, as antimicrobial therapeutic agents.
Derivatives of Pexiganan-related peptides designed to further
optimize the stability and activity of the peptide for potential
applications in vivo include: acylated analogs [50,87,88] and non-
natural amino acid analogs [35,89]. Incorporation of the 12 carbon
lauryl group or amino lauryl group to the N terminus of MSI-78
resulted in increased hemolytic activity and no substantial gains in
antibacterial activity [87]. Non-natural amino acid analogs, speciﬁcally
ﬂuorinated amino acids, including hexaﬂuoroleucine and pentaﬂuor-
ophenylalanine [69] have been substituted into MSI-78 for the
hydrophobic residues leucine, isoleucine and phenylalanine [35,89].
These substitutions allow for retained helical structure in lipids,
micelles, or triﬂuoroethanol [35,89]. In addition, antimicrobial activity
is generally retained or improved in hexaﬂuoroleucine variants with
no additional hemolytic activity. Also, the proteolytic stability of theﬂuorous peptides is greatly enhanced giving rise to potentially
improved bioavailability of the peptides [35,89]. β-peptides [90],
peptoids composed of poly-N-substituted glycines [91], and cationic
oligourea polymers [92] have also been designed to mimic the
structure and amphipathic nature of Pexiganan, but have shown to be
not susceptible to proteolytic degradation.
Synergistic capability of Pexiganan has been evaluated against
bacteria present in the bloodstreams of neutopenic febrile patients
including P. aeruginosa, E. coli, S. aureus (methicillin resistant and
methicillin susceptible) and S. epidermidis (methicillin resistant and
methicillin susceptible) [93]. MSI-78 appears to act in synergy with β-
lactams which has been attributed to increased ability of the β-
lactams to penetrate the bacterial membrane due to thinning of the
membrane in the presence of the AMP [93]. Sepsis rat models have
also been used to determine the effectiveness of Pexiganan alone and
in combination with β-lactams [94]. The synergistic activity of the
Pexiganan/β-lactam combination is observed for the treatment of
endotoxic shock. The LPS binding ability of Pexiganan is implicated as
a very important aspect of the synergistic effect of these antibiotics
due to the association of endotoxin releasewith β-lactam activity [94].
8. Potential applications
The antimicrobial activity of Pexiganan against a broad spectrum of
bacterial species makes it a promising candidate for the treatment of
bacterial infections. In addition to topical application for the treatment
of diabetic foot ulcers as was studied in clinical trials, the above
described studies imply the potential applicability of Pexiganan for
the treatment of sepsis, particularly in combination with approved
antibacterial agents such as β-lactams. The development of non-
natural amino acid containing or non-peptidic mimics of Pexiganan
could be a key to improving biological stability and bioavailability
while retaining the broad-spectrum activity and low toxicity
characteristics of Pexiganan.
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